Sarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group Disparities
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
CARGO Therapeutics, Inc. (CRGX) was downgraded to a Hold Rating at William Blair
CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The ...
Muscular Dystrophy News23h
Boys with DMD given Elevidys 2 years ago still showing motor gains
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...